Mono Pharmacare Ltd IPO Timeline

Mono Pharmacare Ltd IPO opens on 28-Aug-2023, and closes on 30-Aug-2023. The Mono Pharmacare Ltd IPO bid date is from 28-Aug-2023 to 30-Aug-2023. The Cut-off time for UPI Mandate confirmation is 12 P.M. on the next day of issue closing day.

Event Date
Mono Pharmacare Ltd IPO Opening Date 28-Aug-2023
Mono Pharmacare Ltd IPO Closing Date 30-Aug-2023
Basis of Allotment 04-Sep-2023
Initiation of Refunds 05-Sep-2023
Credit of Shares to Demat 06-Sep-2023
Mono Pharmacare Ltd IPO Listing Date 07-Sep-2023

Mono Pharmacare Ltd IPO Lot Size

Mono Pharmacare Ltd IPO lot size is 4000 shares. A retail-individual investor can apply for up to 1 lots (4000 shares or 112000).

Application Lots Shares Amount
Minimum 1 4000 ₹112000
Maximum 1 4000 ₹112000

Mono Pharmacare Ltd IPO Details

Mono Pharmacare Ltd IPO Date 28-Aug-2023 to 30-Aug-2023
Mono Pharmacare Ltd IPO Face Value Shares of ₹10 per share
Mono Pharmacare Ltd IPO Price ₹28 per share
Mono Pharmacare Ltd IPO Lot Size 4000
Issue Size Shares of ₹10 (aggregating up to ₹14.84 Cr)
Fresh Issue Shares of ₹10 (aggregating up to ₹13.78 Cr)
Offer for Sale -
Issue Type Book Building - SME
Listing At NSE - SME
QIB Shares Offered -
Retail Shares Offered -
NII (HNI) Shares Offered -
Company Promoters Panilam Lakhatariya, Supal Lakhatariya.

Objects of the Issue

The company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:

  • 1 To meet the working capital requirements
  • 2 General corporate purposes

Company Financials

Mono Pharmacare Ltd Financial Information (Restated)

Period Ended Total Assets Total Revenue Profit After Tax
03-2024 45.40 72.42 2.44
03-2023 29.07 14.11 0.54
Amount in ₹ Crore
  • Experienced promoters and management team with industry knowledge and an established track record.
  • Asset-light business model and competitive products.
  • Scalable Business Model.
  • Wide and diverse range of product offerings.
  • The company relies on third parties for manufacturing products of the Company.
  • The company are yet to receive No Objection Certificate ("NoC") from banks, and its yet to create charge with Registrar of Companies ("RoC") in respect of those loan facilities availed.
  • In past, the company has undertaken and may continue to undertake strategic investments, acquisitions and mergers in the future, which may be difficult to integrate and manage. Its future success depends on its ability to achieve and manage growth, whether through internal growth or strategic acquisitions.
  • The company is involved in high volume - low margin business. Any disruption in its turnover or failure to regularly grow the same may have a material adverse effect on its business, results of operations and financial condition.
  • The company top ten customers contribute majority of its revenues from operations. Any loss of business from one or more of them may adversely affect its revenues and profitability.
  • The company business largely depends on the performance of its distributors. Any non-performance by these distributors may adversely affect its business operations, profitability and cash flows.
  • The company typically do not enter into long-term agreements with its customers, and an inability to continue to engage with them would have a material adverse effect on its business, results of operations and financial condition.
  • The company is involved in certain legal proceedings, which, if determined adversely, may affect its business and financial condition.
  • The company do not own the premises in which its registered office and warehouses are located and the same are on lease arrangement. Any termination of such lease/license and/or non-renewal thereof could adversely affect its operations.
  • The Company has availed unsecured loans with a total outstanding amount of Rs. 271.93 lakhs as of December 31, 2022, that may be recalled by the lenders at any time.
  • The company has entered into and may continue to enter into related party transactions and there can be no assurance that such transactions have been on favourable terms.
  • If the company cannot respond adequately to the increased competition its expect to face, the company will lose market share and its profits will decline, which will adversely affect its business, results of operations and financial condition.
  • The company marketing & distribution activities are exposed to fluctuations in the prices of materials.
  • The company Promoters and Directors have interests in certain entities, which are in businesses similar to its and this may result in potential conflict of interest with it.
  • The company require high working capital for its smooth day to day operations of business and any discontinuance or its inability to acquire adequate working capital timely and on favourable terms may have an adverse effect on its operations, profitability and growth prospects.
  • The Company's management will have flexibility in utilizing the net proceeds from the issue and the deployment of the net proceeds from the issue is not subject to any monitoring by any independent agency.
  • The company Promoter, Directors and Key Managerial Personnel may have interest in the Company, other than reimbursement of expenses incurred, remuneration or other benefits received.
  • The availability of counterfeit drugs, such as drugs passed off by others as its products, could adversely affect the company goodwill and results of operations.
  • The company insurance coverage may not adequately protect its against potential risk, and this may have a material adverse effect on its business.
  • The company could become liable to customers, suffer adverse publicity and incur substantial costs as a result of deficiency in its products, which in turn could adversely affect the value of our brand, and its sales could be diminished if the company is associated with negative publicity.
  • The company success is dependent on its management team, key managerial personnel and skilled manpower. its inability to attract and retain key personnel or the loss of services of its key personnel may have an adverse effect on the company business prospects.
  • The company business requires it to obtain and renew certain registrations, licenses, approvals, NoCs and permits in the ordinary course of its business. The company inability to obtain, renew or maintain its statutory and regulatory permits and approvals required to operate its business may have a material adverse effect on the company business, financial condition and results of operations.
  • The company has not independently verified certain data in this Draft Red Herring Prospectus.
  • The company Promoter and members of the Promoter Group will continue jointly to retain majority control over the Company after the issue, which will allow them to determine the outcome of matters submitted to shareholders for approval.
  • The Company does not own any trademarks including that of the logo used for representing the Company and its business. Its use logo registered in the name of one of the company promoters, Panilam Lakhatariya. Thus, its may be exposed to the risk that their trademark may be affected by events beyond its control and that the company promoter may not prevent its from using it in the future.
  • The Company's trademarks are not registered as on date of this DRHP. However, applications for registration its trademarks have been filed with the trademark authority. Its may be unable to adequately protect the company intellectual property and/ or be subject to claims alleging breach of third-party intellectual property rights.
  • If the company inadvertently infringe on the patents of others, its business may be adversely affected.
  • The company has certain amount of outstanding indebtedness, which requires significant cash flows to service and are subject to certain conditions and restrictions in terms of its financing arrangements, which restricts the company ability to conduct its business and operations in the manner the company desire.
  • The company may not be successful in implementing its business strategies.
  • The company has not identified any alternate source of financing the 'Objects of the Issue'. If the company fail to mobilize resources as per its plans, the company growth plans may be affected.
  • The company has issued equity shares during the last one year at a price that may be below the issue Price. Further more, the average cost of acquisition of equity shares by its promoters could be lower than the issue price.
  • The company Promoters have provided personal guarantees to certain loan facilities availed by it, which if revoked may require alternative guarantees, repayment of amounts due or termination of the facilities.
  • The company inability to manage inventory in an effective manner could adversely affect its business.
  • The company could be harmed by employee misconduct or errors that are difficult to detect and any such incidences could adversely affect its financial condition, results of operations and reputation.
  • There have been some instances of delayed filing in the past with the Registrar of Companies which may attract penalties.
  • Any future issuance of Equity Shares may dilute the shareholding of the investor, or any sale of Equity Shares by its Promoter or other significant shareholder(s) may adversely affect the trading price of the Equity Shares.
  • The company is being promoted by a first- generation entrepreneur.
  • The requirements of being a listed company may strain its resources.
  • The company ability to pay dividends in the future will depend upon future earnings, financial condition, cash flows, working capital requirements and capital expenditures.
  • Reliance has been placed on declarations furnished by Directors for the details of their profiles included in this DRHP.
  • The Equity Shares have never been publicly traded, and, after the Issue, the Equity Shares may experience price and volume fluctuations, and an active trading market for the Equity Shares may not develop. Further, the price of the Equity Shares may be volatile, and you may be unable to resell the Equity Shares at or above the Issue Price, or at all.
  • The trading volume and market price of the Equity Shares may be volatile following the Issue.
  • There are restrictions on daily weekly monthly movement in the price of the equity shares, which may adversely affect the shareholder's ability to sell for the price at which it can sell, equity shares at a particular point in time.
  • Increasing operational efficiency.
  • Broaden and deepen presence in existing product portfolio.
  • Enhance customer base by entering new geographies.
  • To increase brand visibility.
  • Customer satisfaction.

Mono Pharmacare Ltd IPO Promoter Holding

Pre Issue Share Holding 81.02%
Post Issue Share Holding 56.71%

Mono Pharmacare Ltd IPO Subscription Status (Bidding Detail)

The Mono Pharmacare Ltd IPO is subscribed 12.7743 times on Aug 30, 2023 05:00:00 PM. The public issue subscribed - times in the retail category, - times in the QIB category, and - times in the NII category. Check Day by Day Subscription Details (Live Status)

Category QIB NII Retail Employee Total
Subscription (times) - - - - 12.7743

Mono Pharmacare Ltd IPO Prospectus

Mono Pharmacare Ltd IPO Listing Date

Listing Date 07 Sep 23
BSE Script 78964
NSE Symbol MONOPHARMA
Listing In NSE - SME
ISIN INE0OIP01012
IPO Price ₹28
Face Value ₹10

Mono Pharmacare Ltd IPO Registrar

Bigshare Services Pvt Ltd

Phone: 022-6263 8200
Email: ipo@bigshareonline.com
Website: www.bigshareonline.com

Mono Pharmacare Ltd IPO Lead Manager(s)

  1. Unistone Capital Pvt Ltd

FAQs on Mono Pharmacare Ltd IPO

Mono Pharmacare Ltd IPO, which opens for subscription from 28-Aug-2023 to 30-Aug-2023 has an issue size of ₹14.84 crore. The issue type is book building issue.

In case of pre-apply, your IPO order will be placed on the Exchange as soon as the official bidding for Mono Pharmacare Ltd IPO begins. You will receive a UPI request within 24 hours after the bidding period opens.

Mono Pharmacare Ltd IPO Opens for subscription from 28-Aug-2023 to 30-Aug-2023.

The lot size of Mono Pharmacare Ltd is 4000 shares. Retail investors can subscribe to minimum 1 lot and maximum 1 lots. The minimum and maximum application value is ₹112000 and ₹112000 respectively.

Allotment date for Mono Pharmacare Ltd is 04-Sep-2023 and refund of application amount (in case allotment is not received) will begin from 05-Sep-2023. If your allotment goes through, then shares will be credited in your Demat account by 06-Sep-2023.

The registrar for Mono Pharmacare Ltd IPO is Bigshare Services Pvt Ltd . You can check your IPO allotment status on the registrar's website.

The shares of Mono Pharmacare Ltd are proposed to be listed on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Power your investments with our smart trading platforms

mobilefooterimg
  • app_download_icon_img
    10 million+
    App downloads
  • 1_Click_icon_img
    1-Click
    Order Placement
  • higherreturns_icon_img
    2,203 Crore+
    Average Daily Turnover
Download App
App_Download_QRCode